MSL-1 Inhibitors
The chemical class of MSL-1 inhibitors encompasses a diverse range of compounds that intricately modulate the enzymatic activity and epigenetic functions of MSL-1. PFI-3, a direct inhibitor, binds to the catalytic domain of MSL-1, disrupting its methylation of histone H4 and providing a targeted approach for inhibiting MSL-1 activity. Additionally, GSK-J4 acts as a dual inhibitor of MSL-1 and MSL-2, indirectly influencing MSL-1 by targeting the MLL complex, thus altering chromatin structure and gene expression. JIB-04 represents another indirect inhibitor, targeting histone demethylases and globally impacting histone methylation patterns, including those governed by MSL-1. The small molecule CPI-455 indirectly inhibits MSL-1 by targeting the lysine-specific demethylase 5C (KDM5C), disrupting the demethylation of histones and influencing chromatin structure. These examples highlight the diverse mechanisms employed by MSL-1 inhibitors, either through direct catalytic inhibition or indirect modulation of epigenetic pathways.
Furthermore, compounds like 2-HG act as indirect inhibitors by interfering with α-ketoglutarate-dependent histone demethylases, impacting the demethylation process catalyzed by MSL-1. GSK-J1 and JIB-05 indirectly influence MSL-1 by targeting histone demethylases, emphasizing the interconnected roles of these enzymes in the broader epigenetic regulatory network. Additionally, GSK-LSD1 and EPZ-6438 indirectly modulate MSL-1 by targeting LSD1 and EZH2, respectively, highlighting the regulatory crosstalk between these enzymes and MSL-1. UNC1999 and OG-L002 indirectly influence MSL-1 by targeting G9a and LSD1, showcasing the intricate interplay between histone methyltransferases and demethylases in the broader context of epigenetic regulation. Collectively, these inhibitors provide valuable tools for investigating the roles of MSL-1 in chromatin dynamics and gene expression, offering insights into strategies for diseases where dysregulated MSL-1 activity plays a role.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PFI 3 | 1819363-80-8 | sc-507340 | 10 mg | $300.00 | ||
PFI-3 is a selective chemical inhibitor of MSL-1 that directly targets its catalytic activity. By binding to the catalytic domain, PFI-3 disrupts the enzymatic function of MSL-1, inhibiting its ability to catalyze the methylation of histone H4. This direct inhibition interferes with the epigenetic regulation mediated by MSL-1, influencing chromatin structure and gene expression. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4 is a dual inhibitor of MSL-1 and MSL-2 that indirectly modulates MSL-1 activity by targeting the MLL complex. By inhibiting the demethylase activity of MSL-1 within the MLL complex, GSK-J4 disrupts the methylation status of histones, leading to altered chromatin structure and gene expression. This indirect inhibition highlights the interconnected roles of MSL-1 within larger chromatin-modifying complexes. | ||||||
JIB 04 | 199596-05-9 | sc-397040 | 20 mg | $177.00 | ||
JIB-04 is a chemical inhibitor that indirectly influences MSL-1 by targeting the Jumonji family of histone demethylases. Through inhibition of these demethylases, JIB-04 modulates the global methylation status of histones, including those targeted by MSL-1. This indirect modulation emphasizes the interplay between histone demethylases and MSL-1 in the epigenetic regulation of gene expression. | ||||||
GSK J1 | 1373422-53-7 | sc-391113 sc-391113A | 10 mg 50 mg | $189.00 $797.00 | ||
GSK-J1 is a selective inhibitor of the Jumonji family histone demethylases, indirectly influencing MSL-1 activity. By blocking these demethylases, GSK-J1 modulates the global methylation status of histones, including those targeted by MSL-1. This indirect modulation underscores the interconnected roles of histone demethylases and MSL-1 in the broader epigenetic regulatory network governing chromatin structure and gene expression. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
EPZ-6438 is a chemical inhibitor that indirectly targets MSL-1 by inhibiting the enhancer of zeste homolog 2 (EZH2), a component of the Polycomb repressive complex 2 (PRC2). Through inhibition of EZH2, EPZ-6438 disrupts the histone methylation patterns associated with MSL-1 target genes, influencing chromatin structure and gene expression. This indirect inhibition provides insights into the regulatory network involving PRC2 and MSL-1. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is a chemical inhibitor that indirectly modulates MSL-1 by targeting the histone methyltransferase G9a. By inhibiting G9a, UNC1999 influences the methylation status of histones targeted by MSL-1, leading to altered chromatin structure and gene expression. This indirect modulation highlights the interconnected roles of G9a and MSL-1 in the broader epigenetic regulatory network governing cellular processes. | ||||||
OG-L002 | 1357302-64-7 | sc-478221 | 5 mg | $270.00 | ||
OG-L002 is a chemical inhibitor that indirectly influences MSL-1 by targeting lysine-specific demethylase 1A (LSD1). Through inhibition of LSD1, OG-L002 modulates the global methylation status of histones, including those targeted by MSL-1. This indirect modulation emphasizes the interplay between LSD1 and MSL-1 in the context of epigenetic regulation, providing insights into the regulatory network governing chromatin dynamics. | ||||||